A new clinical trial at the University of Miami Miller School of Medicine will be the first in the U.S. to focus on using mesenchymal stem cells to treat Alzheimer’s Disease. “We believe infusions of stem cells have the potential to be beneficial to individuals with Alzheimer’s disease,” said Bernard S. Baumel, M.D., assistant professor of neurology, the principal investigator for the phase 1 clinical trial.
Breakthrough in Mitochondrial DiseasesRead About It
Progress in Stem Cell TreatmentsRead About It
Moving Day 2015More . . .
ALS Team Accepts Ice Bucket Challenge
The Northern Manhattan Study, a collaboration between the Miller School of Medicine’s Department of Neurology and the Neurological Institute at Columbia University that started in 1990 and is believed to be the longest-running cohort study with a Hispanic majority, has received an $8.5 million, five-year NIH grant to begin a directional shift that puts new emphasis on dementia and cognitive impairment.
A new University of Miami study, aimed at identifying early signs of Alzheimer’s disease and other neurocognitive decline among Latinos and Hispanics, could help delay or even prevent its onset thanks to a $5.67 million, five-year grant from the National Institute on Aging.